VEGFA and gastric cancer: Bevacizumab, a monoclonal antibody that targets VEGF-A, was first evaluated in the perioperative treatment of gastric cancer in a British phase II/III trial, ST03, in combination with ECX (epirubicin, cisplatin, and capecitabine).